Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review

Frontiers in Aging Neuroscience

Volumn 5, Issue JUL, 2013, Pages

  Moreth, Jens ^a   Mavoungou, Chrystelle ^a   Schindowski, Katharina ^a  

^a Biberach University of Applied Science   (Germany)

Author keywords

CSF; Dementia; Mode of action; Passive immunization; Pharmacogenetics and pharmacogenomics; Plasma increase; Regulatory strategy; Therapeutic monoclonal antibodies

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; BIOLOGICAL MARKER; CRENEZUMAB; PLACEBO; SOLANEZUMAB;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; COGNITION; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG MONITORING; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD AND DRUG ADMINISTRATION; GENETIC PREDISPOSITION; GENOTYPE; HALF LIFE TIME; HUMAN; IMMUNOPRECIPITATION; IMMUNOTHERAPY; IN VIVO STUDY; LONGITUDINAL STUDY; MILD COGNITIVE IMPAIRMENT; MOLECULAR WEIGHT; PATIENT SELECTION; PHARMACOGENETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN POLYMORPHISM; RESEARCH DIAGNOSTIC CRITERIA; STEADY STATE; STEREOSPECIFICITY; ULTRACENTRIFUGATION; WESTERN BLOTTING;

EID: 84883544430     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2013.00025     Document Type: Article

References (62)

1. Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., et al. (2012). An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J. Neurosci. 32, 9677-9689. doi: 10.1523/JNEUROSCI.4742-11.2012
2. Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., et al. (2010). Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat. Struct. Mol. Biol. 17, 561-567. doi: 10.1038/nsmb.1799
3. Alzheimer's Disease International. (2009). World Alzheimer Report 2009. Available online at: http://www.alz.co.uk/research/world-report
4. Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., et al. (2005). Globular amyloid beta-peptide oligomer a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95, 834-847. doi: 10.1111/j.1471-4159.2005.03407.x
5. Barten, D. M., Guss, V. L., Corsa, J. A., Loo, A., Hansel, S. B., Zheng, M., et al. (2005). Dynamics of beta-amyloid reductions in brain, cerebrospinal fluid, and plasma of beta-amyloid precursor protein transgenic mice treated with a gamma-secretase inhibitor. J. Pharmacol. Exp. Ther. 312, 635-643. doi: 10.1124/jpet.104.075408
6. Benilova, I., Karran, E., and De Strooper, B. (2012). The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357. doi: 10.1038/nn.3028
7. Bitan, G., Fradinger, E. A., Spring, S. M., and Teplow, D. B. (2005). Neurotoxic protein oligomers what you see is not always what you get. Amyloid 12, 88-95. doi: 10.1080/13506120500106958
8. Blennow, K., Hampel, H., Weiner, M., and Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131-144. doi: 10.1038/nrneurol.2010.4
9. Blennow, K., Zetterberg, H., Rinne, J. O., Salloway, S., Wei, J., Black, R., et al. (2012). Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer Disease. Arch. Neurol. 69, 1002-1010. doi: 10.1001/archneurol.2012.90
10. Broersen, K., Rousseau, F., and Schymkowitz, J. (2010). The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation. Alzheimers Res. Ther. 2, 12. doi: 10.1186/alzrt36
11. Clarke, E. E., and Shearman, M. S. (2000). Quantitation of amyloid-beta peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay. J. Neurosci. Methods 102, 61-68. doi: 10.1016/S0165-0270(00)00280-6
12. Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., et al. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913. doi: 10.1038/nm890
13. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., and Holtzman, D. M. (2002). Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267. doi: 10.1126/science.1067568
14. Di Carlo, M., Giacomazza, D., and San Biagio, P. L. (2012). Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. J. Phys. Condens. Matter 24:244102. doi: 10.1088/0953-8984/24/24/244102
15. Dubois, B., Feldman, H., Jacova, C., Dekosky, S., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet 6, 734-746. doi: 10.1016/S1474-4422(07)70178-3
16. European Medicines Agency. (2011a). European Medicines Agency Releases Qualification Opinion on Diagnosis of Pre-Dementia Alzheimer's for Public Consultation. Available online at: http://www.ema.europa.eu/ema/index.jsp? curl=pages/news_and_events/news/2011/10/news_detail_001359.jspandmid=WC0b01ac058004d5c1. (Accessed January 30, 2013).
17. European Medicines Agency. (2011b). First Clinical Biomarker Qualification Released for Public Consultation. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/02/news_detail_001207.jspandmid=WC0b01ac058004d5c1. (Accessed March 3, 2013).
18. European Medicines Agency. (2011c). Qualification Opinion of Alzheimer's Disease Novel Methodologies/Biomarkers for the use of CSF AB 1-42 and t-tau Signature and/or PET-Amyloid Imaging (Positive/Negative) as a Biomarkers for Enrichment, for use in Regulatory Clinical Trials in Mild. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2011/12/WC500118365.pdf. (Accessed January 30, 2013).
19. Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S.-Y., Dence, C. S., Shah, A. R., et al. (2006). Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512-519. doi: 10.1002/ana.20730
20. Fagan, A. M., and Perrin, R. J. (2012). Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark. Med. 6, 455-476. doi: 10.2217/bmm.12.42
21. Farlow, M., Arnold, S. E., Van Dyck, C. H., Aisen, P. S., Snider, B. J., Porsteinsson, A. P., et al. (2012). Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's Dement. 8, 261-271. doi: 10.1016/j.jalz.2011.09.224
22. Food and Drug Administration. (2012a). FDA Approves Imaging Drug Amyvid. Available online at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm299678.htm. (Accessed January 30, 2013).
23. Food and Drug Administration. (2012b). FY 2012 Innovative Drug Approvals. Available online at: http://www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/ucm330859.pdf. (Accessed March 27, 2013).
24. Funke, S. A., Birkmann, E., and Willbold, D. (2009). Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease. Curr. Alzheimer Res. 6, 285-289. doi: 10.2174/156720509788486536
25. Ghersi-Egea, J. F., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., and Fenstermacher, J. D. (1996). Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67, 880-883. doi: 10.1046/j.1471-4159.1996.67020880.x
26. Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., et al. (2004). Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J. Biol. Chem. 279, 45897-45908. doi: 10.1074/jbc.M407668200
27. GlaxoSmithKline. (2011). A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients with Alzheimer's Disease. Available online at: http://www.gskclinicalstudyregister. com/result_comp_list.jsp?phase=AllandstudyType=Allandpopulation=Allandmarketing=Noandcompound=GSK933776. (Accessed June 1, 2012).
28. Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101 -112. doi: 10.1038/nrm2101
29. Hansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andreasson, U., Londos, E., et al. (2010). Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer' s disease in patients with mild cognitive impairment. Neurobiol. Aging 31, 357-367. doi: 10.1016/j.neurobiolaging.2008.03.027
30. Hoshi, M., Sato, M., Matsumoto, S., Noguchi, A., Yasutake, K., Yoshida, N., et al. (2003). Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. U.S.A. 100, 6370-6375. doi: 10.1073/pnas.1237107100
31. Ito, S., Ohtsuki, S., and Terasaki, T. (2006). Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci. Res. 56, 246-252. doi: 10.1016/j.neures.2006.07.006
32. Iwata, N., Higuchi, M., and Saido, T. C. (2005). Metabolism of amyloid-h peptide and Alzheimer' s disease. Brain 108, 403-430.
33. Johnson & Johnson. (2012). Johnson & Johnson Announces Discontinuation Of Phase 3 Development of Bapineuzumab Intravenous (IV) In Mild-To-Moderate Alzheimer's Disease. 2012. Available online at: http://www.jnj.com/connect/news/product/johnson-and-johnson-announces-discontinuation-of-phase-3- development-of-bapineuzumab-intravenous-iv-in-mild-to-moderate-alzheimers-disease
34. Johnson-Wood, K., Lee, M., Motter, R., Hu, K., Gordon, G., Barbour, R., et al. (1997). Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 94:1550. doi: 10.1073/pnas.94.4.1550
35. Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., and Younkin, S. G. (2001). Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381.
36. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., et al. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489. doi: 10.1126/science.1079469
37. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., et al. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453. doi: 10.1073/pnas.95.11.6448
38. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., et al. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357. doi: 10.1038/nature04533
39. Lilly, E. (2012). Lilly Announces Detailed Results of the Phase 3 Solanezumab Expedition Studies Following a Presentation of the Independent Analyses by the Alzheimer's Disease Cooperative Study (ADCS). Available online at: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=702211
40. Matthews, G., and Bader, V. (2012). Indipendent Analysis of Solanezumab Provides Evidence that Compound may remove Amyloid from Brain in Alzheimer's Disease. Clinical Trials on Alzheimer's Disease (Press Release). Available online at: http://www.ctad.fr/07-download/Congres2012/PressRelease/Sola- Release_29Oct2012.pdf. (Accessed November 5, 2012).
41. Mavoungou, C., and Schindowski, K. (2013). "Immunotherapy with anti-Amyloid-beta antibodies in Alzheimer's disease: a critical review on the molecules in the pipelines with regulatory considerations," in Frontiers in Clinical Drug Research - Alzheimer Disorders, Vol. 1, ed A. U. Rahman (Oak Park: Bentham Science Publishers), 3-85.
42. McDonald, J. M., Savva, G. M., Brayne, C., Welzel, A. T., Forster, G., Shankar, G. M., et al. (2010). The presence of sodium dodecyl sulphate-stable abeta dimers is strongly associated with alzheimer-type dementia. Brain J. Neurol. 133, 1328-1341.
43. Moreth, J., Kroker, K. S., Schwanzar, D., Schnack, C., Von Arnim, C. A. F., Hengerer, B., et al. (2013). Globular and protofibrillar Aβ aggregates impair neurotransmission by different mechanisms. Biochemistry 52, 1466-1476. doi: 10.1021/bi3016444
44. O'Nuallain, B., Freir, D. B., Nicoll, A. J., Risse, E., Ferguson, N., Herron, C. E., et al. (2010). Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci. 30, 14411-14419. doi: 10.1523/JNEUROSCI.3537-10.2010
45. Park, J. E., Dorner-Ciossek, C., Hoerer, S., Kussmaul, L., Lenter, M., Zimmermann, K., et al. (2012). A-Beta binding polypeptides. U.S. Patent 8337845 B2 filed, 2012.
46. Pfizer. (2013). Pfizer Pipeline our Medicines in Development. Available online at: http://www.pfizer.com/research/product_pipeline/product_pipeline.jsp. (Accessed March 27, 2013).
47. Reed, M. N., Hofmeister, J. J., Jungbauer, L., Welzel, A. T., Yu, C., Sherman, M. A., et al. (2011). Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol. Aging 32, 1784-1794. doi: 10.1016/j.neurobiolaging.2009.11.007
48. Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., et al. (2007). Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13, 1029 -1031. doi: 10.1038/nm1635
49. Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070. doi: 10.1212/WNL.0b013e3181c67808
50. Salloway, S., Sperling, R., Honig, L., Porsteinsson, A., Sabbagh, M., Liu, E., et al. (2012). A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E β 4 non-carriers. Eur. J. Neurol. 19, SC312.
51. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
52. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842. doi: 10.1038/nm1782
53. Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., et al. (2000). Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499. doi: 10.1172/JCI10498
54. Sperling, R., Salloway, S., Raskind, M., Ferris, S., Liu, E., Yuen, E., et al. (2012). A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E β 4 carriers. Eur. J. Neurol. 19, SC3012.
55. Strobel, G., and Bowman Rogers, M. (2012). CTAD (2012) in Monte Carlo: Getting Preclinical Trials Ship Shape. Alzheimer Research Forum. Available online at: http://www.alzforum.org/new/pdf/CTAD2012.pdf. (Accessed January 14, 2013).
56. Terry, R. D. (2006). Alzheimer's disease and the aging brain. J. Geriatric Psychiatry Neurol. 19, 125-128. doi: 10.1177/0891988706291079
57. Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., et al. (1999). Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945-25952. doi: 10.1074/jbc.274.36.25945
58. Walsh, D. M., and Selkoe, D. J. (2007). A beta oligomers - a decade of discovery. J. Neurochem. 101, 1172-1184. doi: 10.1111/j.1471-4159.2006.04426.x
59. Walsh, D. M., Townsend, M., Podlisny, M. B., Shankar, G. M., Fadeeva, J. V., El Agnaf, O., et al. (2005). Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci. 25, 2455-2462. doi: 10.1523/JNEUROSCI.4391- 04.2005
60. Zetterberg, H. (2008). Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease. Recent Pat. CNS Drug Discov. 3, 109-111. doi: 10.2174/157488908784534595
61. Zetterberg, H., Blennow, K., and Hanse, E. (2010). Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp. Gerontol. 45, 23-29. doi: 10.1016/j.exger.2009.08.002
62. Zlokovic, B. V., Ghiso, J., Mackic, J. B., McComb, J. G., Weiss, M. H., and Frangione, B. (1993). Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem. Biophys. Res. Commun. 197, 1034-1040. doi: 10.1006/bbrc.1993.2582